SCOPUS 정보 검색 플랫폼

Volumn 150, Issue 3, 2000, Pages 347-348

Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine

(2) Boot, E a De Haan, L a

a UNIVERSITY OF AMSTERDAM (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CREATINE KINASE MM; HALOPERIDOL; LOXAPINE; MELPERONE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GRANULOCYTOPENIA; HUMAN; LETTER; MALE; MUSCLE DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033938231 PISSN: 00333158 EISSN: None Source Type: Journal
DOI: 10.1007/s002130000464 Document Type: Letter

Times cited : (29)

References (7)

1
- 0022514367
- Racial differences in serum creatine kinase levels
- HR Black H Quallich CB Gareleck 1986 Racial differences in serum creatine kinase levels Am J Med 81 479 487 1:CAS:528:DyaL28XlvVyhu7s%3D 3752149 10.1016/0002-9343(86)90303-7 Black HR, Quallich H, Gareleck CB (1986) Racial differences in serum creatine kinase levels. Am J Med 81:479–487
- (1986) Am J Med , vol.81 , pp. 479-487
- Black, HR¹ Quallich, H² Gareleck, CB³

2
- 0033535429
- Neuroleptic malignant syndrome after treatment with olanzapine
- C Emborg B Kongevej 1999 Neuroleptic malignant syndrome after treatment with olanzapine Ugeskr Laeger 161 1424 1425 1:STN:280:DyaK1M7osFKksA%3D%3D 10085753 Emborg C, Kongevej B (1999) Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskr Laeger 161:1424–1425
- (1999) Ugeskr Laeger , vol.161 , pp. 1424-1425
- Emborg, C¹ Kongevej, B²

3
- 0022388674
- Neuroleptic malignant syndrome
- BS Fogel RJ Goldberg 1985 Neuroleptic malignant syndrome N Engl J Med 313 1292 10.1056/NEJM198511143132015 Fogel BS, Goldberg RJ (1985) Neuroleptic malignant syndrome. N Engl J Med 313:1292
- (1985) N Engl J Med , vol.313 , pp. 1292
- Fogel, BS¹ Goldberg, RJ²

4
- 0033142688
- Olanzapine and NMS
- C Hickey C Stewart S Lippmann 1999 Olanzapine and NMS Psychiatr Serv 50 836 837 1:STN:280:DyaK1MzgtFKqtw%3D%3D 10375159 Hickey C, Stewart C, Lippmann S (1999) Olanzapine and NMS. Psychiatr Serv 50:836–837
- (1999) Psychiatr Serv , vol.50 , pp. 836-837
- Hickey, C¹ Stewart, C² Lippmann, S³

5
- 0032450594
- Neuroleptic malignant syndrome associated with olanzapine
- V Johnson G Bruxner 1998 Neuroleptic malignant syndrome associated with olanzapine Aust NZJ Psychiatry 32 884 886 1:STN:280:DyaK1M7otFyntA%3D%3D 10.3109/00048679809073880 Johnson V, Bruxner G (1998) Neuroleptic malignant syndrome associated with olanzapine. Aust NZJ Psychiatry 32:884–886
- (1998) Aust NZJ Psychiatry , vol.32 , pp. 884-886
- Johnson, V¹ Bruxner, G²

6
- 0027958424
- Creatine kinase elevations with clozapine
- MS Keshavan J Stecker RK Kambhampati 1994 Creatine kinase elevations with clozapine Br J Psychiatry 164 118 120 1:STN:280:DyaK2c7osVOksw%3D%3D 7802755 10.1192/bjp.164.1.118 Keshavan MS, Stecker J, Kambhampati RK (1994) Creatine kinase elevations with clozapine. Br J Psychiatry 164:118–120
- (1994) Br J Psychiatry , vol.164 , pp. 118-120
- Keshavan, MS¹ Stecker, J² Kambhampati, RK³

7
- 0030272215
- Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment
- HY Meltzer PA Cola M Parsa 1996 Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment Neuropsychopharmacology 15 395 405 1:CAS:528:DyaK28XmtlyntbY%3D 8887994 10.1016/0893-133X(95)00276-J Meltzer HY, Cola PA, Parsa M (1996) Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15:395–405
- (1996) Neuropsychopharmacology , vol.15 , pp. 395-405
- Meltzer, HY¹ Cola, PA² Parsa, M³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.